Grant of Options

RNS Number : 7063A

Omega Diagnostics Group PLC

30 September 2015

 

Omega Diagnostics Group PLC

("Omega" or the "Company")

Grant of Options

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that yesterday evening its Remuneration Committee awarded Colin King, Chief Operating Officer,  1,200,000 share options under the Company's EMI Share Option Scheme.  Half of these are subject to performance criterion 1 and half subject to performance criterion 2.

The Options have been awarded at an exercise price of 13.0p (closing mid-market price on 28 September 2015).  Following the grant yesterday, these options represent Colin King's only interest in the Company.

Performance conditions:

Performance criterion 1: The options have a three year vesting period and after they are fully vested, they cannot be exercised until the share price has been at 50p or higher on at least one occasion at any time on or after the vesting period.

Performance criteria 2:  In addition to performance criterion 1, the Company's adjusted earnings per share must exhibit a 10% cumulative growth rate over the three-year period beginning 1 April 2016.

Contacts:

Omega Diagnostics Group PLC	Tel: [phone]
Andrew Shepherd, Chief Executive
Kieron Harbinson, Group Finance Director    Jag Grewal, Group Sales and Marketing Director	www.omegadiagnostics.com
finnCap Ltd	Tel: [phone]
Geoff Nash/James Thompson (Corporate Finance) Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

MSCGIGDCSGXBGUG